Company presentation
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Company presentation

on

  • 502 views

 

Statistics

Views

Total Views
502
Views on SlideShare
345
Embed Views
157

Actions

Likes
0
Downloads
1
Comments
0

1 Embed 157

http://www.chimeraresearchgroup.com 157

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Company presentation Presentation Transcript

  • 1. Vintafolide in NSCLC - Phase 2 Study Design & Results • Leading cause of cancer death Unmet need • Overall Survival <6 months • 80% of patients folate receptor positive • Eligibility: Vintafolide – Failed >2 prior therapies Evaluated in – Folate receptor positive Advanced Patients • Advanced disease: – 42% failed ≥4 prior therapies – Bulky disease - median tumor length of 7.9 cm • Met primary endpoint of clinical benefit Positive Results • Well tolerated • Significant improvement in OS in FR(100%) patients 23
  • 2. Positive Signal - Single Agent Vintafolide in FR(100%) NSCLC Progression Free Survival Overall SurvivalProbability of Survival Probability of Survival FR(100%) FR(100%) FR(10-90%) FR(10-90%) Weeks from First Administration of Vintafolide Weeks from First Administration of Vintafolide Progression Free Survival FR(100%) FR(10%-90%) Overall Survival FR(100%) FR(10-90%) N=14 N=14 N=14 N=14 Median PFS months. 7.2 1.7 Median OS months. 10.9 3.4 Hazard Ratio (2-sided p-value) 0.326 p=0.028 Hazard Ratio (2-sided p-value) 0.539 p=0.202Note: FR(x%) – x refers to percent of target lesions determined to be positive for the folate receptor by the etarfolatide scan. 25
  • 3. Promising Phase 2 Vintafolide Results in NSCLC vs.Standard Regimens Regimens Response Rate PFS (months) Survival (months) First-line Navelbine/Cisplatin 19% - 9.2 Taxol/Cisplatin 25% 4.3 (TTP) 9.3 Gem/Cisplatin 26% 5.2 (TTP) 9.0 Taxotere/Cisplatin 32% 4.9 (TTP) 10.9 Taxol/Carbo/Avastina 35% 6.2 12.3 Gem/Cisplatin/Avastina 34% 6.7 - First-line with maintenance Alimta post platinum doublets - 4.0 13.4 Alimta post Alimta/platinum - 4.1 Not yet matured Tarceva post platinum doublets - 2.8 12.0 Second and third-line Taxotere – second-line 6% 1.9b ;2.8c 5.7b ;7.5c Iressa – third-line 11% - - Tarceva – second and third-line 9% 2.3 6.7 Vintafolide FR(100%) – Median 3rd line 7% 7.2 10.9 a Non-squamous NSCLC; b against BSC; c against Navelbine/Iphosphamide 26
  • 4. TARGET trial design – Vintafolide in 2nd line NSCLC Preclinical studies support Phase 2b Design combining with Docetaxel 2nd Line NSCLC 1600Tumor Volume (mm3) 1400 1200 Etarfolatide Folate Receptor 1000 Scan 800 KB Control 600 FR(100%) Vintafolide only 400 Docetaxel 200 Vintafolide + Docetaxel 1:1:1 Randomization 0 7 14 21 28 35 42 49 56 PTI (days) Vintafolide Vintafolide Docetaxel /Docetaxel (n=60) (n=60) (n=60) 25
  • 5. Promising Vintafolide results compared to standardregimens in 2nd and 3rd line NSCLC Regimens Response Rate PFS (months) Survival (months) Taxotere 6% 1.9a ;2.8b 5.7a ;7.5b 2nd line Alimta vs. Taxotere 9% vs. 8% 2.9 vs. 2.9 8.3 vs. 7.9 2nd line Tarceva vs. placebo 9% vs. 1% 2.3 vs. 1.8 6.7 vs. 4.7 2nd & 3rd line EC145 FR(100%) 7% 7.2 10.9 70%  ≥3  prior  Txa TTPD against Navelbine/Iphosphamide; bTTPD against BSC 23